132 related articles for article (PubMed ID: 37666675)
1. PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion.
Xu J; Wang Y; Li P; Chen C; Jiang Z; Wang X; Liu P
Br J Haematol; 2023 Nov; 203(4):599-613. PubMed ID: 37666675
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
[TBL] [Abstract][Full Text] [Related]
3. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
4. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
[TBL] [Abstract][Full Text] [Related]
6. [Investigation of chromosome 1 aberrations in patients with multiple myeloma using cIg-FISH method and its significance].
Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2010 Dec; 31(12):804-8. PubMed ID: 21223735
[TBL] [Abstract][Full Text] [Related]
7. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib.
Du C; Mao X; Xu Y; Yan Y; Yuan C; Du X; Liu J; Fan H; Wang Q; Sui W; Deng S; Fu M; Li Z; Li C; Zhao J; Yi S; Liu L; Hao M; Zou D; Zhao Y; Qiu L; An G
Leuk Lymphoma; 2020 May; 61(5):1201-1210. PubMed ID: 31842644
[TBL] [Abstract][Full Text] [Related]
8. [Research Advances in Multiple Myeloma with Chromosome 1q21 Amplification].
Wang C; Hu R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):649-652. PubMed ID: 35400366
[TBL] [Abstract][Full Text] [Related]
9. Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets.
Burroughs Garcìa J; Eufemiese RA; Storti P; Sammarelli G; Craviotto L; Todaro G; Toscani D; Marchica V; Giuliani N
Cells; 2021 Jun; 10(6):. PubMed ID: 34205916
[TBL] [Abstract][Full Text] [Related]
10. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
11. Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma.
Hanamura I
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445467
[TBL] [Abstract][Full Text] [Related]
12. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
Shaughnessy J
Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
[TBL] [Abstract][Full Text] [Related]
13. ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma.
Wu C; Yang T; Liu Y; Lu Y; Yang Y; Liu X; Liu X; Ye L; Sun Y; Wang X; Li Q; Yang P; Yu X; Gao S; Kumar S; Jin F; Dai Y; Li W
Cancer Med; 2018 Aug; 7(8):3899-3911. PubMed ID: 29926531
[TBL] [Abstract][Full Text] [Related]
14. The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides.
Xu J; Xu T; Yang Y; Wang W; Li J; Ren Y; Gu S; Chen C; Wei Z; Zhuang J; Wang Z; Ji L; Cheng L; Wang W; Cheng Z; Ke Y; Yuan L; Liu P
Leuk Lymphoma; 2020 Oct; 61(10):2351-2364. PubMed ID: 32519901
[TBL] [Abstract][Full Text] [Related]
15. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of 1q21 Gain in Multiple Myeloma.
Chen D; Zhou D; Xu J; Zhou R; Ouyang J; Chen B
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e159-e164. PubMed ID: 30685183
[TBL] [Abstract][Full Text] [Related]
17. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
Kastritis E; Migkou M; Dalampira D; Gavriatopoulou M; Fotiou D; Roussou M; Kanellias N; Ntanasis-Stathopoulos I; Malandrakis P; Theodorakakou F; Sevastoudi A; Eleutherakis-Papaiakovou E; Triantafyllou T; Terpos E; Katodritou E; Dimopoulos MA
Am J Hematol; 2022 Sep; 97(9):1142-1149. PubMed ID: 35731917
[TBL] [Abstract][Full Text] [Related]
18. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
Gao L; Liu Y; Li Y; Feng L; Wang Z; Wen L; Wang F; Huang X; Lu J; Lai Y
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):535-544. PubMed ID: 35292207
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
[TBL] [Abstract][Full Text] [Related]
20. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
Jin Y; Yu X; Du J; Li H; Tang W; Jia C; Zan Y; Chen M; Zhang Y; Yu M; Rong W; Zhou D; Zhuang J
Ann Hematol; 2021 May; 100(5):1251-1260. PubMed ID: 33686491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
